

### e-News December 2025

## Update to Pharmacist Drug Administration Rule - Effective 1/7/2026

Section 4729.45 of the Revised Code and recent updates to rule 4729:1-3-03 of the Administrative Code (effective 1/7/2026) authorize a pharmacist to administer, by subcutaneous or intramuscular injection, any of the following dangerous drugs as long as the drug that is to be administered has been prescribed by a physician, certified nurse-midwife, clinical nurse specialist, or certified nurse practitioner; is administered in accordance with a prescriber-authorized protocol; and the individual to whom the drug was prescribed has an ongoing physician-patient or nurse-patient relationship with the physician or nurse:

- An addiction treatment drug administered in a long-acting or extended-release form, which
  may include any medication indicated for relapse prevention. NOTE: This includes the
  administration of controlled substances (e.g., buprenorphine) used to treat addiction in a
  long-acting or extended-release form.
- An antipsychotic drug administered in a long-acting or extended-release form.
- A human immunodeficiency virus treatment or prevention drug administered in a longacting or extended-release form.
- Hydroxyprogesterone caproate for pregnant women.
- Medroxyprogesterone acetate for non-pregnant women.
- Cobalamin (including the administration of cyanocobalamin, hydroxocobalamin, or any other FDA-approved B<sub>12</sub> injection).
- Antibiotics.
- Denosumab or romosozumab.
- Methotrexate for non-emergent conditions.
- Heparin, low molecular weight heparin, and factor Xa inhibitors.

For questions regarding pharmacist administration of injectable medications, review the frequently asked questions document at: <a href="https://www.pharmacy.ohio.gov/administration">www.pharmacy.ohio.gov/administration</a>. If you need additional information, the most expedient way to have your questions answered will be to e-mail the Board office by visiting: <a href="https://www.pharmacy.ohio.gov/contact.aspx">http://www.pharmacy.ohio.gov/contact.aspx</a>.

## Electronic Positive Identification Requirements Effective January 15, 2027

Effective January 15, 2027, amendments to **OAC 4729:5-5-04** will require, with limited exceptions, that all **Ohio outpatient pharmacies** adopt electronic positive identification as part of the pharmacy's record keeping system. This means that once effective, the rule will not permit the use of hardcopy records and manual signatures to capture positive identification except for the following:

- Compounding and the dispensation of compounded drugs; and
- Ancillary services as defined in rule 4729:5-5-02.1 of the Administrative Code.

**IMPORTANT:** This change does not impact institutional pharmacies (except those that operate outpatient pharmacies), non-resident pharmacies, and other terminal distributors (EMS, clinics, OTPs, etc.).

To review the upcoming amendments to the rule, visit: www.pharmacy.ohio.gov/positivelDchange.

#### **Waiver Request Process**

A waiver of the requirement for electronic positive identification may be granted by the Board upon written request of an outpatient pharmacy. All requests must be submitted in writing using this form: www.pharmacy.ohio.gov/waiver.

**IMPORTANT:** The Board of Pharmacy will begin to consider waivers for review starting January 1, 2026. Waiver requests submitted prior to this date **will not** be reviewed.

**NOTE:** The Board reserves the right to request additional information and documentation to render a decision as to whether to grant a waiver. Waivers will be granted on a limited basis and requests that do not include all the required information will not be reviewed by Board staff.

### Ten Common Prescriber Clinic and Medical Spa Violations

Since the beginning of 2025, the Ohio Board of Pharmacy has **summarily suspended** more than 30 clinics and medical spas (med spas) after determining there is clear and convincing evidence they pose a danger of immediate and serious harm to others.

To educate current and future licensees, the Board developed this **guidance**, which highlights ten common violations identified at prescriber clinics and med spas: http://www.pharmacy.ohio.gov/Top10

These examples come directly from citations issued by the Board. To review these citations in detail, visit: www.pharmacy.ohio.gov/Suspend.

#### **Have Questions?**

If you have any questions about the operation of your licensed location, please do not hesitate to reach out to the Ohio Board of Pharmacy by email (contact@pharmacy.ohio.gov) or by phone (614-466-4143). We have a pharmacist on duty Monday-Friday during normal business hours to assist you with any questions or concerns.

Current licensees are also encouraged to contact their local Board inspector. If you do not have that contact information, please call the Board office (614-466-4143) and ask to speak with the Compliance and Enforcement Department.

# Resolution: Computer Generated Faxes and Images for Compounded Total Parenteral Nutrition

OAC 4729:5-3-11 states no prescriptions may be transmitted by means of an electronic prescription transmission system or computerized prescriber order entry system that converts the prescription or order into a computer-generated fax or scanned image. There are several exceptions to this prohibition in the rule.

On November 3, 2025, the Board approved a resolution permitting the transmission of prescriptions for compounded total parenteral nutrition for dispensation by a pharmacy via an

electronic system that converts the prescription into a computer-generated fax or scanned image. **NOTE:** This does not require a Board-approved third-party intermediary or closed system.

### Rules for Stakeholder Feedback - Winter 2025-2026 Rules

Date Issued: 12/8/2025 Comments Due: 1/15/2026

The following rules are being distributed for stakeholder comment:

- Rule 4729:5-3-25 | Electronic product verification. (NEW)
- Rule 4729:5-4-01 | Disciplinary actions. (AMEND) (applies to terminal distributors of dangerous drugs)
- Rule 4729:6-4-01 | Disciplinary actions. (AMEND) (applies to drug distributors)
- Rule 4729:6-1-01 | Definitions distributors of dangerous drugs. (AMEND)
- Rule 4729-3-01 | Disqualifying offenses. (AMEND)
- Rule 4729-5-01 | Recognized and approved schools of pharmacy. (AMEND)

Comments on the proposed rules will be accepted until close of business on Thursday, January 15, 2026. Please send all comments to the following email address: RuleComments@pharmacy.ohio.gov.

The proposed rule text can accessed here: www.pharmacy.ohio.gov/Winter2025-2026Rules.

## **Be Vigilant - Watch Out for Scammers!**

BOARD STAFF DO NOT ASK FOR MONEY OVER THE PHONE OR VIA EMAIL TO RESOLVE PENDING INVESTIGATIONS. WHEN IN DOUBT, PLEASE CONTACT THE BOARD IF YOU BELIEVE YOU ARE THE TARGET OF A SCAM.

The Ohio Board of Pharmacy continues to learn that licensees are being targeted by scammers who claim to work for various governmental agencies (Board of Pharmacy, DEA, FBI, Department of Justice, etc.) to obtain money from the target. The Board strongly encourages licensees to be alert to avoid scammers.

Scammers may try to initiate contact via phone calls, emails, faxes, and letters purporting to originate from various state and federal agencies that include allegations of drug trafficking and threats of suspension against the target's license.

Board of Pharmacy investigators will not ask for fine payment or personal/sensitive information over the phone and will never contact licensees via fax. As a reminder, administrative fines issued by the Board are not paid via gift cards or cryptocurrency. If the Board of Pharmacy is conducting an investigation and that individual faces action against their license, they will receive an official notice of opportunity for a hearing either via certified mail, personal service, or electronic registered mail.

If you are contacted by a scammer, please report this information using the Board's online complaint form: www.pharmacy.ohio.gov/complaint. Additionally, reports should be made to your local law enforcement agency.

If you receive any suspicious calls or correspondence purporting to be from the Board of Pharmacy, we encourage you to call (614-466-4143) or email (contact@pharmacy.ohio.gov) the Board to confirm its legitimacy.



People call, text, and chat the 988 Lifeline to talk about a lot of emotional needs—not just thoughts of suicide. Whatever your reason, the #988Lifeline is there to help. There is hope.







## Ohio Board of Pharmacy Mike DeWine, Governor | Steven W. Schierholt, Executive Director

Ohio Board of Pharmacy | 77 S. High St 17th Floor | Columbus, OH 43215 US

<u>Unsubscribe</u> | <u>Constant Contact Data Notice</u>